The DSO De Novo Boom: Why Dental Groups Are Building Instead of Buying
Several DSOs are diversifying beyond acquisitions by ramping up de novo practice development, a shift driven by tighter deal supply, valuation pressure, and the operational appeal of building from scratch. Smile Partners launched its first de novo as a deliberate break from its acquisition-only model, while Park Dental Partners is directing post-IPO capital toward new office openings in existing markets. The appeal is practical: de novos offer DSOs full control over patient experience, staffing culture, and brand consistency from day one, without integration costs of acquired practices. At a moment when acquisition targets are harder to find and multiples remain elevated, de novo development is emerging as a high-conviction growth strategy for platforms with strong operational infrastructure.
For PE-backed dental platforms weighing capital deployment, this piece captures the de novo shift in concrete terms — naming specific DSOs making the pivot. Operators should assess their own organic development capacity now, before competitive density in key markets makes de novo economics harder to justify.
While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.
Why are DSOs increasingly pursuing de novo development over acquisitions?
De novo development is gaining favor as practice supply tightens and acquisition multiples rise. Building from scratch eliminates the premium paid for existing patient panels and goodwill, allows DSOs to install their own systems and culture from day one, and provides control over location, design, and provider selection. Organizations like Smile Partners have launched dedicated de novo programs as a core growth pillar alongside acquisitions.
What are the primary risks of de novo dental practice development?
The main risk is ramp time — a new practice typically takes 18 to 36 months to reach mature production levels, generating losses during that period. Real estate selection is difficult to reverse. Provider recruitment for new locations is often harder than retaining an acquired practice’s existing dentist. DSOs managing large de novo pipelines need strong cash reserves and conservative production ramp assumptions in their financial models.
How do de novo economics compare to acquisition economics for DSOs?
De novo development typically requires lower upfront capital than acquisition since there is no goodwill payment, but carries higher execution risk and longer payback periods. Well-located de novos in high-growth markets can generate superior long-term returns compared to acquisitions at 7x to 10x EBITDA — but only when site selection, provider recruitment, and ramp support are executed at a consistently high level.